9,112 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Vise Technologies Inc.

Posted by Stanley Muller on Aug 21st, 2026

Vise Technologies Inc. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,112 shares of the medical research company’s stock, valued at approximately $4,568,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. Legacy Wealth Managment LLC ID lifted its stake in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the period. Allied Private Wealth LLC acquired a new stake in Thermo Fisher Scientific during the second quarter valued at $26,000. High Note Wealth LLC increased its holdings in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $28,000. Finally, JPL Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth about $28,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 63,493 shares of company stock worth $37,657,681. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.4%

TMO stock opened at $628.24 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a market cap of $232.29 billion, a price-to-earnings ratio of 33.79, a PEG ratio of 2.50 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average of $539.33 and a two-hundred day moving average of $508.86.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Piper Sandler boosted their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research report on Monday, July 6th. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Read Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.